Notícias Pasithea Therapeutics Corporation - KTTA | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Pasithea Therapeutics Corporation (KTTA)
Pasithea Therapeutics Corporation (KTTA) Notícias

Pasithea Therapeutics Corporation (KTTA)

1,24

0,06

(5,08%)

No fechamento: 21 Março 5:00PM

Atrasado por 15 minutos

1,1799

-0,0601

( -4,85% )

Após o horário de negociação: 6:55PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Form 4 - Statement of changes in beneficial ownership of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Pasithea Therapeutics

Strategic Fixed Income C...

Highstreet token

Bnp Paribas Issuance

Augur Reputation v2

Knightswan Acquisition

RSE Archive (GM)

Gladstone Commercial

Bmo Us Dollar Money Mark...

WisdomTree Commodity Sec...

BNP Paribas Issuance

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições